Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this trial for the two schedules of PXD101 and idarubicin combination treatment is to determine the safety and tolerance (Maximum Tolerated Dose, Dose Limiting Toxicity) and explore the efficacy (Response rate (CR or PR), using the response criteria of the International Working Group (Cheson et al 2003)).(CR will in this protocol include CRi, CRc, CRm – see section 9.0 in the protocol).
Critère d'inclusion
- Patients with AML in need of new treatment principles